Wockhardt (NSE:WOCKPHARMA) Marketable Securities: ₹0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:WOCKPHARMA Wockhardt Ltd NSE:WOCKPHARMA
60 GF Score
Price ₹2,179.40
GF Value ₹1,467.51
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Wockhardt Marketable Securities?

Wockhardt NSE:WOCKPHARMA -1.86% 60 Marketable Securities is ₹0 Mil as of Jun. 2026. GuruFocus rates NSE:WOCKPHARMA with a GF Score™ of 60/100 and a GF Value™ of ₹1,467.51 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Wockhardt's Marketable Securities for the quarter that ended in Jun. 2026 was ₹0 Mil.

Wockhardt's annual Marketable Securities increased from Mar. 2024 (₹0 Mil) to Mar. 2025 (₹4,220 Mil) but then declined from Mar. 2025 (₹4,220 Mil) to Mar. 2026 (₹4,120 Mil).

Wockhardt  (NSE:WOCKPHARMA) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Wockhardt Marketable Securities Related Terms

Wockhardt Marketable Securities Historical Data

* Premium members only.

The historical data trend for Wockhardt's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Wockhardt Marketable Securities Chart

Wockhardt Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 4,220.00 4,120.00

Wockhardt Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 8,010.00 0.00 4,120.00 0.00
NSE:WOCKPHARMA
60GF Score
Wockhardt Ltd NSE:WOCKPHARMA
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Wockhardt Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of ₹0 Mil mean?
Wockhardt (NSE:WOCKPHARMA) has a Marketable Securities of ₹0 Mil as of Jun. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Wockhardt and its competitors.
Is Wockhardt's Marketable Securities too high?
Wockhardt's current Marketable Securities is ₹0 Mil. Overall, Wockhardt has a GF Score™ of 60/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Wockhardt's Marketable Securities compare to ZTS?
Wockhardt's Marketable Securities of ₹0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Drug Manufacturers company?
A good Marketable Securities depends on the Drug Manufacturers industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Wockhardt and its competitors. Wockhardt's current Marketable Securities is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Wockhardt stock overvalued right now?
Based on GuruFocus' analysis, Wockhardt (NSE:WOCKPHARMA) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹1,467.51, compared to a current price of ₹2,179.40 — trading 48.5% above its estimated fair value. The current Marketable Securities is ₹0 Mil. Wockhardt's overall GF Score™ is 60/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Wockhardt (NSE:WOCKPHARMA), the current Marketable Securities is ₹0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Wockhardt (NSE:WOCKPHARMA) Overvalued in 2026?

Based on GuruFocus' analysis, Wockhardt stock appears to be overvalued. The current stock price of ₹2,179.40 is trading 48.5% above its estimated GF Value™ of ₹1,467.51. GuruFocus considers Wockhardt to be Significantly Overvalued.

Key valuation signals for NSE:WOCKPHARMA:

  • Marketable Securities: ₹0 Mil
  • GF Value™: ₹1,467.51 vs. price of ₹2,179.40 (48.5% above fair value)
  • GF Score™: 60/100 with 5 warning signs

No single metric tells the full story. See the NSE:WOCKPHARMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Wockhardt Business Description

Other Exchanges 532300:India
Address Bandra-Kurla Complex, Wockhardt Towers, Bandra East, Mumbai, MH, IND, 400051
Wockhardt Ltd is a drug manufacturing company focusing on pharmaceutical and biotechnology products. The group is involved in new drug discovery, contract manufacturing, API, vaccines, and branded pharmaceuticals business. In addition, it operates a chain of super-specialty hospitals. Its novel antibiotic platform has various assets, such as Zaynich (WCK 5222); Miqnaf (Nafithromycin), a macrolide-class respiratory antibiotic; Ertapenem-Zidebactam (WCK 6777); Foviscu (WCK 2482), an antibiotic for Gram-negative infections; and Odrate (WCK 6777), among others. The group is mainly engaged in the pharmaceutical business, which is considered its only reportable business segment. Geographically, it generates maximum revenue from Europe, followed by India, the USA, and the Rest of the world.
60GF Score

Get the complete analysis for NSE:WOCKPHARMA

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹2,179.40
Price
₹1,467.51
GF Value